Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
The recommended dose is 60 mg every 4 to 6 hours when using immediate release
tablets. When using extended release tablets the recommended dose is 120 mg
every 12 hours or 240 mg every 24 hours.
Pseudoephedrine should not be combined with monoamine oxidase inhibitors (MAOIs)
because such combinations may cause an acute hypertensive episode. Examples of
MAOIs include rasagiline (Azilect), selegiline (Eldepryl, Zelapar),
isocarboxazid (Marplan), phenelzine (Nardil), and tranylcypromine (Parnate).
PREGNANCY AND BREASTFEEDING SAFETY:
Use of pseudoephedrine by
pregnant women has not been adequately evaluated.
Pseudoephedrine is secreted in breast milk. However, it is considered safe to
use while nursing.
Pseudoephedrine is a decongestant used for reducing nasal congestion caused
by allergies or the common cold. Pseudoephedrine causes blood vessels in the
nasal passages to shrink (vasoconstrict). Vasoconstriction reduces nasal
congestion by preventing fluid from draining from blood vessels into nasal
passages. Pseudoephedrine also directly stimulates beta-adrenergic receptors and
causes relaxation of bronchioles, as well as increased heart rate and